Trial Profile

Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
Indications Asthma
Focus Pharmacodynamics; Therapeutic Use
Acronyms RECOGNISE
Sponsors AstraZeneca

Most Recent Events

18 Aug 2020 Status changed from recruiting to completed.
18 Jun 2019 Planned End Date changed from 1 Oct 2019 to 1 Nov 2019.
18 Jun 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com